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Syntex (U.S.A.) Inc., Institute for Research Data Management, 3401 Hillview Ave, Palo Alto, 
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Abstraet--A generic Monte Carlo simulation system is described. The system is designed to simulate two 
subpopulations growing within a heterogeneous t mor. The dynamic distribution of cells between the two 
populations is determined by selective and inductive pressures, as defined by a deterministic or 
phenomenological h zard. The dynamic nature of the hazard is independently specified by the system user, 
and the design of the system allows for rapid customization of the software. The cell cycle is simulated 
as a series of maturation chambers, each defined such that the duration time in each chamber isdistributed 
in accordance with an exponential distribution. This technique allows the user to specify the mean and 
standard eviation of the lifelength distribution as though it were distributed in accordance with a 
gamma-distribution. The basic design of the system is described in this paper. Two extant systems are 
used as illustrative xamples throughout. 
INTRODUCTION 
Tumor cell heterogeneity may be expressed over a broad spectrum of possible phenotypes [1, 2]. 
One area of particular interest is the expression of chemoresistance as a phenotype, with the 
resultant establishment of drug resistant subpopulations within a heterogeneous tumor [1, 3, 4]. 
Another is the differential expression of immuno-susceptibility, which can confer a selective 
advantage upon a subclone within an emerging tumor. In this paper we present he design of a 
simulation system which simulates the dynamics of individual cell populations which express 
differential sensitivities to genetic ytotoxic agents. The mathematical model which underlies the 
simulation system is a "hybrid", in the sense that it describes the population dynamics of two kinds 
of cells (sensitive and resistant) as a stochastic birth-death-migration process, while describing the 
transition probabilities as deterministic or phenomenological functions of an agent's (cytotoxic) 
concentration. The probability that a cell either dies or alters its phenotype in the presence of the 
agent, at a given level of  activity, represents he intrinsic apacity of the "average" cell to respond 
to the biochemical/biophysical a tivities of the agent. However, in vivo, the level of agent present 
at the cellular target site (e.g. nuclear DNA, cell surface antigens etc.) may be a complex function 
of time, external agent concentration, feedback etc. What this simulation system does is associate 
a transition probability (either cell death or change of phenotype) with the level of agent at the 
target site in the tumor. In our system, it is the responsibility of the user to provide a reasonable 
deterministic or phenomenological model of this hazard. 
In our simulation system, resistance may be differentially expressed by either disparate responses 
to some fixed level of agent, as in cells that are resistant to drugs due to an overexpression f repair 
genes, or as a fixed response to differential levels of the agent at the target site within the cell, as 
with cells that are resistant to drugs due to decreased drug levels in the nucleus. We discuss the 
details of resistance with respect o our model parameters below. 
THE MODEL 
In our system, a genetic mathematical model describes the stochastic dynamics observed in the 
cell populations via a birth-death-migration process (see Fig. 1). Transition probabilities which 
describe the process during any small time step, dt, depend functionally upon the level or 
concentration f the cytotoxic agent at the target site. Specific models using this generic foundation 
have already been developed. One model describes the dynamics of sensitive and multi-drug 
resistant phenotypes in the presence of a cytotoxic drug [5], and the other describes the emergence 
of immuno-resistant subclones of a tumor in the presence of an active anti-tumor response [6-8]. 
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Fig. 1. The birth-death-migration process within the context of selective forces in a heterogeneous t mor. 
Sensitive and resistant cells mature, die, reproduce and alter their phenotypes based upon the transition 
probabilities defined within the text. 
The portion of the generic model which describes the population dynamics is the same in both. 
The portion of the model which describes the deterministic nature of the agent-dependent transition 
rates varies from system to system. 
Assumptions and definitions 
The standard assumptions underlying a generic birth--death-migration model (i.e. particle 
independence, random lifelengths etc.) have been described in detail elsewhere [5, 7, 8]. Given these 
assumptions, we then define the following notation for the development of the population model: 
Pij(t) = prob{i sensitive cells and j resistant cells are present in the system at time t}; 
G(s, z, t) = bivariate (joint) probability generating function for the (random) number of sensitive 
and resistant cells in the system at time t; 
M~(t) = first factorial moment (mean) of the distribution of sensitive cells in the system at 
time t; 
Mr(t) = first factorial moment (mean) of the distribution of resistant cells in the system at 
time t; 
M~(t) = second factorial moment of the distribution of sensitive cells in the system at time t; 
Mr(t) = second factorial moment of the distribution of resistant cells in the system at time t; 
and 
Msr(t) = product moment of the distribution of resistant cells in the system at time t. 
To visualize the dynamics of the process more clearly, define the discrete 2-space of ordered pairs 
of non-negative integers as the probability event space of interest (i.e. we are only concerned with 
cell populations that have non-negative numbers of cells in them). At each time t, we specify Pij(t) 
for each ordered pair (i,j) in the probability event space. The stochastic portion of the model 
derives the conditional probability that the system is in state (i,j) at time (t + dr), given that it 
was in an adjacent state at time t (i.e. we assume that two transitions within the event space in 
any small time, dr, are of order dt). Formally, we define the transition probabilities: 
ds" dt = prob{sensitive c ll d_ies in the interval (t, t + dt)}; 
dr" dt = prob{resistant cell d_ies in the interval (t, t + dt)}; 
bs" dt = br" dt = b.  dt = prob{a daughter pair is created (_born) due to mitosis during the 
interval (t, t + dt)}, 
as" dt = prob{a sensitive cell acquires the resistant phenotype during the interval (t, t + dt)} 
and 
at" dt = prob{a resistant cell acquires the sensitive phenotype during the interval (t, t + dt)}. 
Note that even though the transition probabilities are denoted as constants, in the hybrid model 
they are, in fact, dependent upon the distribution of cytotoxic agent at the target site of the 
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"average" resistant or sensitive cell. By allowing these values to vary, one can confer differential 
transition rates upon the two cell populations. One must remember, however, that these differential 
rates will be expressed as deterministic or phenomenological functions of the time-dependent agent 
profile. 
Population dynamics 
The stochastic model describing population growth is shown in Fig. 1. Briefly, cells either die, 
divide (acting as a single birth in the model), acquire a new phenotype or rest. These dynamics 
are described by the forward Kolmogorov-Chapman equation: 
dPaj/dt = (i + l)dsPi+ l,j(t) + (j  + 1)drP~j+ l(t) + (i - 1)bPi_lj(t) + ( j  -- 1)bP~,/_l(t) 
+ (i + 1)as ei 4- I , j  -- 1 (t) + (j + 1)ar P,- ,j+, (t) -- Pu(t) [i(ds + b + as) + j  (d~ + b + a,)]. (1) 
Multiplying each of the/ j  equations by the dummy variables ~ and z j and summing over all i and 
j yields the joint probability generating function for the two distinct (random) population sizes. 
Let s, z e [0, 1], and define 
G(s ,z , t )= ~ ~ Pu(t)s'z/. 
i f f i0 j f f i0  
Then, 
~G/at = [(1 - s)(ds - sb) + (z - s)as] OGles + [(1 - z ) (4  - zb) + (s - z)ad OG/Oz. (2) 
Define Ms(t) = ~G/as and M,(t)  = aG/az at s = z = 1. Ms(t ) is the first factorial moment of the 
distribution of sensitive cell population sizes at time t. Similarly, Mr(t) is the first factorial moment 
of the distribution of resistant cell sizes at time t. Taking the appropriate partial derivatives in 
equation (2), and setting s = z = 1, we derive the ordinary differential equation (ODE) pair for 
Ms(t) and M,(t): 
and 
dMJdt  = -[ds + as + b]Ms(t) + arMr(t), 
dMr/dt = - [d  r + ar + b]Mr(t) + asMs(t). 
The second factorial moments are defined as 
M~(t) = 02G/~s 2, 
Mrr(t ) = ~2G /t~z2 
and 
Msr(t  ) = 02G /ds • Oz, 
when s = z = 1. Taking appropriate partial derivatives of equation (2) yields: 
dM~/dt = bMs - 2[d, + as - b ]M~(t) + arMsr(t), 
dMrddt = bMr -  2[dr + a~ - b]Mrr(t) + asMsr(t) 
and 
(3) 
dMs,/dt = - {[d s+ as - b] + [dr + ar - b]}Msr(t) + asM.(t)  + arM, r(t). (4) 
Initial conditions for equations (3) and (4) are a function of the initial size and distribution of the 
two phenotypes in the cell population. 
THE S IMULATION SYSTEM 
Equations (3) and (4) are intractable in closed form except when the time-dependence of the 
transition probabilities i extremely simple. Furthermore, ven if the equations could be solved in 
closed form, we could not derive a good estimate for the extinction probabilities of either 
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population at time t. Rather, we have developed a Monte Carlo simulation (described functionally 
in Fig. 2) which simulates the actual stochastic population dynamics encountered in the basic model 
[see equation (1)]. The cell cycle is modeled as a pipeline composed of identical maturation 
chambers (Fig. 3). The lifelengths within each chamber are distributed in accordance with an 
exponential distribution, i.e. the probability of maturing in the interval (t, t + dr) is a constant 
independent of t. This configuration allows for the specification of the total cell lifelength as a 
random variable distributed in accordance with a gamma-distribution. The length of the pipeline 
and the rate of maturation are easily determined ynamically from a user-defined mean and 
standard eviation for the lifelength distribution [6, 7]. 
The mechanistic description of the simulation software is presented in Fig. 2. The system is 
essentially a loop, replicating simulation realizations a specified number of times. Before execution 
begins, the system prompts the user for all parameter data needed to describe the dynamic response 
of the agent in time, the mean and standard eviation of the lifelength distribution, the initial size 
and distribution of the cell populations and the hazard rate for each type of transition. 
At each iteration of the loop, the system advances the simulated time by 30 rain. At each time 
step a cell faces a risk of being killed by the cytotoxic agent, acquiring the opposite phenotype 
(migrating to the opposite pipeline) or maturing (progressing through the chambers of its pipe). 
The chances for both cell death and transformation f phenotype are determined by the dynamic 
distribution of the agent at the target site of the "average" resistant or sensitive cell. 
For each cell in each maturation chamber of each pipeline, we use the following algorithm to 
determine whether a transition should occur: each type of transition is represented as a transition 
probability in the 30-min time step. Rather than calculating a transition probability to determine 
a "success" for each cell in each chamber, one at a time, we treat each chamber as a conglomerate 
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Fig. 2. Functional structure chart for the generic simulation system. Input from and output to the user 
are defined at the second level of processing (outside the simulation loop). This figure shows a 
representational flow of the program. Each box represents a module in the software. The logic within the 
modules i left out of the diagram for reasons of clarity. 
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Fig. 3. Pipelines of maturation chambers which yield a random life length distribution asa gamma-dis- 
tribution. Maturation velocity and pipeline length are calculated according toa user-defined mean and 
standard deviation for the cell population. 
of Bernoulli trials. Therefore, if a chamber contains, say, k cells, we can calculate the probability 
of x successes from k trials by using the standard binomial distribution. A single realization from 
a standard uniform random number generator can be used to determine how many of the k cells 
in the given chamber "succeeded", and will move to the new state. For example, suppose that 2 
cells reside in a chamber, and the transition rate for cell death is 0.25. Then, the probability that 
no cells will die is 0.5625, the probability that both cells will die is 0.0625, and the probability that 
one cell will die is 0.3750. A uniform random variate that falls below 0.5625 results in no deaths, 
a number falling between 0.5625 and 0.9375 results in one cell dying, and a number falling above 
0.9375 results in both cells being removed from the chamber. 
The simulation continues until either all cells are dead or until a user-supplied time limit has been 
exceeded. The entire process is then repeated until the simulation has been run a (user-supplied) 
replicate number of times, The output at each time step is saved in a memory buffer and output 
to a file. The output presently includes the size of each population, the time and the level of agent 
at the target site for both the resistant and sensitive cells. 
The simulation is customized through the box marked "CALCULATE HAZARD PROFILE" 
in Fig. 2. The user may define any set of deterministic or phenomenological onditions to represent 
the distribution of agent in or around the target site of the "average" sensitive and "average" 
resistant cell. Note, that these two hazard levels may be equal, and that resistance may be an 
intrinsic property of the cells and independent of the agent level. We provide two examples of how 
this system may be customized below. 
S IMULAT ION RESULTS 
Immuno-selection 
Michelson [6-8] has used this type of system to address the problem of tumor escape in the 
presence of an active anti-tumor immune response. The target site in this case is the cell surface, 
with immunogenic target structures measured as a concentration per unit area. Two types of escape 
mechanisms were studied. The first models immuno-modulation f the surface target structures, 
as originally defined by Boyse and colleagues [9]. The trigger mechanism for modulation/ 
demodulation is the presence of immuno-active ffectors on the cell surface. Therefore, the 
probability of a cell in one state acquiring the phenotype of the other state depends upon the level 
of immunologically active effectors at the target site (i.e. the cell surface). The second model 
assumes that the only transition allowed from sensitive to resistant phenotype is expressed at 
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mitosis. Resistance thus conferred upon a daughter cell is permanent, and results in alteration of 
the cell surface antigen configuration. In both studies, Michelson assumes that the surface 
concentration of target structures i  a measure of immuno-resistance, and that the fewer target 
structures per unit area, the less likely a cell is to be recognized and lysed. 
The initial simulation begins with one immuno-susceptible cell at time zero. The level of the 
immune response is phenomenologically described by two response functions. The first represents 
the anti-tumor activity of non-inductive ffector elements within the immune response (e.g. NK 
cells). The second represents a complimentary inductive wave (e.g. cytotoxic T cells). By 
manipulating six parameters for each response profile (minimum activity, maximum activity, time 
of onset, time to maximum response, duration of maximum response and time needed to return 
to baseline levels), the user mimics a wide range of experimental data (e.g. see Michelson [8] for 
a model of Golub's findings in interferon-treated melanoma patients [10, 11]). 
The response profiles are calculated as time-dependent functions at the beginning of each time 
step [7, 8]. The hazard of recognition, conjugation and lysis are calculated as a proportion of a 
maximal in vitro response. The probabilities are scaled by the concentration of target structures 
on the cell surface of the "average" sensitive and "average" resistant cell. Therefore, differential 
transition probabilities for sensitive and resistant cell types are generated for a given anti-tumor 
response. This mechanism of response contrasts well with the mechanism employed by cells 
expressing the "classical" multi-drug resistant phenotype (discussed below). 
Michelson [7, 8] used this model to study the emergence of immuno-resistant subclones, 
subclinical extinction of nascent tumors (i.e. immune surveillance) and the effects of differing tumor 
cell phenotypes upon the immune surveillance hypothesis. Briefly, he found that clonal survival in 
the presence of an active immune response is as much cell dependent as it is response dependent. 
The cell lifelength, its modulatory capacity, its rate of mutation and their interactions all affect a 
cells ability to survive. 
Multi-drug resistance 
Michelson and Slate [5] have used this simulation system to investigate the response of tumor 
cells to cytotoxic drugs in cancer therapy. The target site in this case may be the DNA within the 
nucleus. It is assumed that the risk of cytotoxic death is directly proportional to the concentration 
of drug at the target site. The level of the drug at the target site is deterministically described by 
a simple two-compartment model of the micro-pharmacology within a typical cell (see Ref. [5] for 
complete details). Eight parameters (four for each cell type: drug uptake into the cytoplasm; drug 
uptake at the target site; drug removal from the cytoplasm; and drug metabolism at the target site) 
are used to derive differential drug dynamics across the two populations. The ODE system is 
integrated at 3-min intervals within each 30-rain time step using a fourth-ordcr Runge-Kutta 
differential equation solver (within the box "CALCULATE HAZARD PROFILE" in Fig. 2). The 
output of the calculation module is the concentration of drug in each compartment of the 
"average" cell (sensitive or resistant) at time t. 
Resistance may also be conferred upon a cell due to intrinsic biochemical mechanisms that 
overcome drug levels that are common across the entire population. Therefore, in this system, the 
user may specify differential hazard rates for cytotoxic ell death given the same level of drug at 
the target site. 
Simulation studies to test the sufficiency of each type of resistance mechanism have been run. 
One typical study (an in vitro "washout" experiment) is presented in Fig. 4. The drug was allowed 
to sit in culture for 4 h, at which time the cells were washed and followed for 3 days. Our results 
are qualitatively similar to those observed in our laboratories. While combining these types of 
resistance mechanisms has some basis in experimental observation [12, 13], we have yet to complete 
the simulation studies in this area. Complete statistical analyses for the outputs of a factorial design 
are planned to determine whether the effects of each mechanism are additive or synergistic. 
DISCUSSION 
Tumor heterogeneity, byits very nature, imparts a spectrum of response to hostile factors across 
an entire tumor cell population. Biological heterogeneity within a number of tumor systems has 
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Fig. 4. Typical simulation result for one realization of a "washout" experiment. Cells are dosed/n vitro 
with a given concentration of drug (normalized to 1 unit per unit volume) for 4 h. Excess drug is washed 
away and new medium added to the colony. The dynamics of cell death are followed for 3 days. Panel 
A: cytoplasmic concentration. Panel B: target site concentration. Panel C: cell population sizes. Panel D: 
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been reviewed by Dexter and Leith [1]. One system in particular has been studied in detail. Termed 
DLD-1, this system is a human adenocarcinoma of the colon first extracted from a patient and 
characterized as consisting of two karyotypically and morphologically distinct subpopulations 
[14-17]. Other heterogeneous tumor systems have also been observed in mice [18-20]. 
Modeling of heterogeneous tumors has followed two paths. Goldie and Coldman [21] have 
proposed some of the most notable models based upon a cellular mutation giving rise to single 
agent resistance [21-25]. They have shown that the probability of observing a homogeneous tumor 
quickly tends to zero as the tumor evolves. Their models have initiated a series of experiments o
demonstrate that selection operates on pre-existing variants and predicts that the frequency of 
cross-resistance should be the product of the individual underlying single mutation frequencies. 
A second theoretical strategy has been to model population-wide dynamics. The population 
dynamics of two extant subclones within an ascites tumor has been modeled by Jansson and Revesz 
[26]. They show that theoretical macro-ecology can mimic the micro-ecology observed in a mixed 
population tumor. Michelson et al. [27] extended their model to include an emergence dynamic 
which allows one subpopulation to arise from the other through a permanent biological alteration 
of the cell machinery. The stochastic analog for this model has also been developed [28], and the 
basic results are consistent with the conclusions drawn by Goldie and Coldman. 
In this paper we present a simulation system based upon a generic mathematical model that 
addresses the dynamic emergence and selection of subpopulations in heterogeneous tumors. The 
particular expression of heterogeneity is only important in so far as it forces the modeler to define 
the character of his/her proposed selective pressures. The system simulates mall population 
dynamics that can provide the user with insights into the random dynamics of subpopulation 
emergence, xtinction and selection. 
Tumor heterogeneity with respect to immuno-susceptibility is a case in point. Whether immuno- 
heterogeneity is expressed as a tumor's ability to escape intragenerationally (e.g. modulation) or 
intergenerationally (via a permanent decrease in tumor specific target structures upon the cell 
surfaces at mitosis), the tumor still displays a spectrum of response. If we define immune 
surveillance as the process by which a host's immune system continuously and consistently clears 
malignantly transformed cells at a subclinical stage, and if we assume that the cells are frequently 
transformed to their malignant states due to onslaught by carcinogenic agents, the dynamics of 
the immune response provide the time-dependent selective pressures required in this model. 
Michelson [6-8] phenomenologically modeled the selective pressures of the anti-tumor esponse. 
The shapes of the anti-tumor response waves (non-inductive and inductive responses) are derived 
from the literature. The specific parameters epresenting the relative intensities and dynamics of 
the waves are specified by the user. The dynamics of subpopulation emergence and subsequent 
tumor escape, as derived from the simulations, suggest hat the ultimate escape of the tumor to 
clinical stages is, in fact, as much tumor-dependent as response-dependent. 
The study of drug resistance in cultured cells provides another case in point. In vitro experiments 
suggest that a complicated set of genetic and biochemical changes mitigate drug resistance in tumor 
cells [29-33]. A number of different mechanisms contribute to the phenotype termed "resistant". 
The most common are decreased drug uptake, increased rug efflux, increased rug degradation/ 
metabolism, upregulation of target proteins and alteration of target properties. Combinations of 
these mechanisms can be involved also. 
Additionally, resistance can be categorized as either stable or unstable [34]. The phenotype is
stable when the underlying changes are preserved in the absence of active selection. Unstable 
resistance is characterized by the loss of resistance under the same conditions. Stable resistance is
often associated with chromosomal changes uch as the generation of "homogeneous staining 
regions" (HSRs), while unstably resistant cells often show extrachromosomal alterations, uch as 
the appearance of double minute chromosomes. Furthermore, cells can become resistant o the 
selective agent only (single-drug resistance), or, in some cases, to agents which are structurally and 
mechanistically diverse (multiple or pleiotropic drug resistance) [35-38]. 
In this model, the distribution of drug at the target site of the "average" cell provides the 
deterministic selective pressure. Michelson and Slate [5] have modeled rug distribution within the 
cell (i.e. micro-pharmacology), by using a simple two-compartment model for the cell. The 
simulation system solves the differential equations (a 2 x 2 system) by using a fourth-order 
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Runge--Kutta differential equation solver. Initial results suggest hat the simulation system is able 
to derive qualitatively consistent results with those observed in our laboratories and in the literature 
(see Ref. [5] for details). The selective pressure itself, however, is merely the concentration of drug 
at the target site. More complete models of the micro-pharmacology (including saturable pump 
kinetics) are presently under development. 
In either model, slight modification of the pipeline structure can accommodate the stochastic 
simulation of two cell populations under selective or inductive pressures. The dynamics of the 
selective pressures are the determining factors in the customization of a system. Presently, 
applications such as the effects of differentiation agents on tumor cell populations, and induced 
ratio- or drug resistance due to tumor bed effects are under way. 
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